Successful management of depression with reboxetine in a patient who developed parkinsonism related to paroxetine use
Gespeichert in:
| Veröffentlicht in: | Journal of psychopharmacology (Oxford) 2010-04, Vol.24 (4), p.623-624 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 624 |
|---|---|
| container_issue | 4 |
| container_start_page | 623 |
| container_title | Journal of psychopharmacology (Oxford) |
| container_volume | 24 |
| creator | Kuloglu, M. Caykoylu, A. Ekinci, O. Bayindirli, D. Vural, G. Deniz, O. |
| description | |
| doi_str_mv | 10.1177/0269881108099962 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_746271566</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_0269881108099962</sage_id><sourcerecordid>746271566</sourcerecordid><originalsourceid>FETCH-LOGICAL-c366t-694c26f814f78e12afa0ef139de6a1c952795d36e66be869e5aedcc6c8a08ef83</originalsourceid><addsrcrecordid>eNp1kE1r3TAQRUVpaF4-9l0Vb0pWbjW2NZaWISRtINBFkrXRk0eNUltyJLtJ_31k3msLha4E9547gsPYe-CfANr2M69QSQnAJVdKYfWGbaBBKNtKirdss9bl2h-yo5QeOQdsULxjh6B424habNhyuxhDKdllKEbt9Xcayc9FsEVPU8yFC754dvNDEWkbXmh2ngrnC11MenYr-vwQMvuThjBRn9P4w_kUvEtjngx6zuEc1vz3ekl0wg6sHhKd7t9jdn91eXfxtbz59uX64vymNDXiXKJqTIVWQmNbSVBpqzlZqFVPqMEoUbVK9DUS4pYkKhKaemPQSM0lWVkfs7Pd3SmGp4XS3I0uGRoG7SksqWsbrFoQiJnkO9LEkFIk203RjTr-6oB3q-vuX9d58mF_fNmO1P8d7OVm4OMe0MnowUbtjUt_uKoGACmazJU7LmX93WNYos9S_v_xK9tCllE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>746271566</pqid></control><display><type>article</type><title>Successful management of depression with reboxetine in a patient who developed parkinsonism related to paroxetine use</title><source>Access via SAGE</source><source>MEDLINE</source><creator>Kuloglu, M. ; Caykoylu, A. ; Ekinci, O. ; Bayindirli, D. ; Vural, G. ; Deniz, O.</creator><creatorcontrib>Kuloglu, M. ; Caykoylu, A. ; Ekinci, O. ; Bayindirli, D. ; Vural, G. ; Deniz, O.</creatorcontrib><identifier>ISSN: 0269-8811</identifier><identifier>EISSN: 1461-7285</identifier><identifier>DOI: 10.1177/0269881108099962</identifier><identifier>PMID: 19074535</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><subject>Adrenergic Uptake Inhibitors - therapeutic use ; Adult and adolescent clinical studies ; Antidepressive Agents, Second-Generation - adverse effects ; Biological and medical sciences ; Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases ; Depression ; Depressive Disorder, Major - diagnosis ; Depressive Disorder, Major - drug therapy ; Humans ; Male ; Medical sciences ; Middle Aged ; Mood disorders ; Morpholines - therapeutic use ; Neurology ; Neuropharmacology ; Organic mental disorders. Neuropsychology ; Parkinson Disease, Secondary - chemically induced ; Paroxetine - adverse effects ; Pharmacology. Drug treatments ; Psychiatric Status Rating Scales ; Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer ; Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease) ; Psychology. Psychoanalysis. Psychiatry ; Psychopathology. Psychiatry ; Psychopharmacology ; Serotonin Uptake Inhibitors - adverse effects ; Severity of Illness Index ; Treatment Outcome</subject><ispartof>Journal of psychopharmacology (Oxford), 2010-04, Vol.24 (4), p.623-624</ispartof><rights>2010 British Association for Psychopharmacology</rights><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c366t-694c26f814f78e12afa0ef139de6a1c952795d36e66be869e5aedcc6c8a08ef83</citedby><cites>FETCH-LOGICAL-c366t-694c26f814f78e12afa0ef139de6a1c952795d36e66be869e5aedcc6c8a08ef83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1177/0269881108099962$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1177/0269881108099962$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>314,780,784,21819,27924,27925,43621,43622</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=23111854$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19074535$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kuloglu, M.</creatorcontrib><creatorcontrib>Caykoylu, A.</creatorcontrib><creatorcontrib>Ekinci, O.</creatorcontrib><creatorcontrib>Bayindirli, D.</creatorcontrib><creatorcontrib>Vural, G.</creatorcontrib><creatorcontrib>Deniz, O.</creatorcontrib><title>Successful management of depression with reboxetine in a patient who developed parkinsonism related to paroxetine use</title><title>Journal of psychopharmacology (Oxford)</title><addtitle>J Psychopharmacol</addtitle><subject>Adrenergic Uptake Inhibitors - therapeutic use</subject><subject>Adult and adolescent clinical studies</subject><subject>Antidepressive Agents, Second-Generation - adverse effects</subject><subject>Biological and medical sciences</subject><subject>Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases</subject><subject>Depression</subject><subject>Depressive Disorder, Major - diagnosis</subject><subject>Depressive Disorder, Major - drug therapy</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Mood disorders</subject><subject>Morpholines - therapeutic use</subject><subject>Neurology</subject><subject>Neuropharmacology</subject><subject>Organic mental disorders. Neuropsychology</subject><subject>Parkinson Disease, Secondary - chemically induced</subject><subject>Paroxetine - adverse effects</subject><subject>Pharmacology. Drug treatments</subject><subject>Psychiatric Status Rating Scales</subject><subject>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer</subject><subject>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopathology. Psychiatry</subject><subject>Psychopharmacology</subject><subject>Serotonin Uptake Inhibitors - adverse effects</subject><subject>Severity of Illness Index</subject><subject>Treatment Outcome</subject><issn>0269-8811</issn><issn>1461-7285</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kE1r3TAQRUVpaF4-9l0Vb0pWbjW2NZaWISRtINBFkrXRk0eNUltyJLtJ_31k3msLha4E9547gsPYe-CfANr2M69QSQnAJVdKYfWGbaBBKNtKirdss9bl2h-yo5QeOQdsULxjh6B424habNhyuxhDKdllKEbt9Xcayc9FsEVPU8yFC754dvNDEWkbXmh2ngrnC11MenYr-vwQMvuThjBRn9P4w_kUvEtjngx6zuEc1vz3ekl0wg6sHhKd7t9jdn91eXfxtbz59uX64vymNDXiXKJqTIVWQmNbSVBpqzlZqFVPqMEoUbVK9DUS4pYkKhKaemPQSM0lWVkfs7Pd3SmGp4XS3I0uGRoG7SksqWsbrFoQiJnkO9LEkFIk203RjTr-6oB3q-vuX9d58mF_fNmO1P8d7OVm4OMe0MnowUbtjUt_uKoGACmazJU7LmX93WNYos9S_v_xK9tCllE</recordid><startdate>20100401</startdate><enddate>20100401</enddate><creator>Kuloglu, M.</creator><creator>Caykoylu, A.</creator><creator>Ekinci, O.</creator><creator>Bayindirli, D.</creator><creator>Vural, G.</creator><creator>Deniz, O.</creator><general>SAGE Publications</general><general>Sage Publications</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope></search><sort><creationdate>20100401</creationdate><title>Successful management of depression with reboxetine in a patient who developed parkinsonism related to paroxetine use</title><author>Kuloglu, M. ; Caykoylu, A. ; Ekinci, O. ; Bayindirli, D. ; Vural, G. ; Deniz, O.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c366t-694c26f814f78e12afa0ef139de6a1c952795d36e66be869e5aedcc6c8a08ef83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Adrenergic Uptake Inhibitors - therapeutic use</topic><topic>Adult and adolescent clinical studies</topic><topic>Antidepressive Agents, Second-Generation - adverse effects</topic><topic>Biological and medical sciences</topic><topic>Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases</topic><topic>Depression</topic><topic>Depressive Disorder, Major - diagnosis</topic><topic>Depressive Disorder, Major - drug therapy</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Mood disorders</topic><topic>Morpholines - therapeutic use</topic><topic>Neurology</topic><topic>Neuropharmacology</topic><topic>Organic mental disorders. Neuropsychology</topic><topic>Parkinson Disease, Secondary - chemically induced</topic><topic>Paroxetine - adverse effects</topic><topic>Pharmacology. Drug treatments</topic><topic>Psychiatric Status Rating Scales</topic><topic>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer</topic><topic>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopathology. Psychiatry</topic><topic>Psychopharmacology</topic><topic>Serotonin Uptake Inhibitors - adverse effects</topic><topic>Severity of Illness Index</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kuloglu, M.</creatorcontrib><creatorcontrib>Caykoylu, A.</creatorcontrib><creatorcontrib>Ekinci, O.</creatorcontrib><creatorcontrib>Bayindirli, D.</creatorcontrib><creatorcontrib>Vural, G.</creatorcontrib><creatorcontrib>Deniz, O.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><jtitle>Journal of psychopharmacology (Oxford)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kuloglu, M.</au><au>Caykoylu, A.</au><au>Ekinci, O.</au><au>Bayindirli, D.</au><au>Vural, G.</au><au>Deniz, O.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Successful management of depression with reboxetine in a patient who developed parkinsonism related to paroxetine use</atitle><jtitle>Journal of psychopharmacology (Oxford)</jtitle><addtitle>J Psychopharmacol</addtitle><date>2010-04-01</date><risdate>2010</risdate><volume>24</volume><issue>4</issue><spage>623</spage><epage>624</epage><pages>623-624</pages><issn>0269-8811</issn><eissn>1461-7285</eissn><cop>London, England</cop><pub>SAGE Publications</pub><pmid>19074535</pmid><doi>10.1177/0269881108099962</doi><tpages>2</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0269-8811 |
| ispartof | Journal of psychopharmacology (Oxford), 2010-04, Vol.24 (4), p.623-624 |
| issn | 0269-8811 1461-7285 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_746271566 |
| source | Access via SAGE; MEDLINE |
| subjects | Adrenergic Uptake Inhibitors - therapeutic use Adult and adolescent clinical studies Antidepressive Agents, Second-Generation - adverse effects Biological and medical sciences Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases Depression Depressive Disorder, Major - diagnosis Depressive Disorder, Major - drug therapy Humans Male Medical sciences Middle Aged Mood disorders Morpholines - therapeutic use Neurology Neuropharmacology Organic mental disorders. Neuropsychology Parkinson Disease, Secondary - chemically induced Paroxetine - adverse effects Pharmacology. Drug treatments Psychiatric Status Rating Scales Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease) Psychology. Psychoanalysis. Psychiatry Psychopathology. Psychiatry Psychopharmacology Serotonin Uptake Inhibitors - adverse effects Severity of Illness Index Treatment Outcome |
| title | Successful management of depression with reboxetine in a patient who developed parkinsonism related to paroxetine use |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T15%3A35%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Successful%20management%20of%20depression%20with%20reboxetine%20in%20a%20patient%20who%20developed%20parkinsonism%20related%20to%20paroxetine%20use&rft.jtitle=Journal%20of%20psychopharmacology%20(Oxford)&rft.au=Kuloglu,%20M.&rft.date=2010-04-01&rft.volume=24&rft.issue=4&rft.spage=623&rft.epage=624&rft.pages=623-624&rft.issn=0269-8811&rft.eissn=1461-7285&rft_id=info:doi/10.1177/0269881108099962&rft_dat=%3Cproquest_cross%3E746271566%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=746271566&rft_id=info:pmid/19074535&rft_sage_id=10.1177_0269881108099962&rfr_iscdi=true |